berberine has been researched along with Respiratory Syndrome, Acute, Severe in 1 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " An orally available immunotherapeutic-berberine nanomedicine, named NIT-X, has been developed by our group and has shown significantly increased oral bioavailability of berberine, increased IFN-γ production by CD8+ T cells, and inhibition of mast cell histamine release in vivo, suggesting a protective immune response." | 1.62 | A small molecule compound berberine as an orally active therapeutic candidate against COVID-19 and SARS: A computational and mechanistic study. ( Geliebter, J; Huang, W; Li, K; Li, XM; Maskey, AR; Miao, M; Srivastava, K; Tiwari, R; Toutov, AA; Wang, ZZ; Yang, N, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, ZZ | 1 |
| Li, K | 1 |
| Maskey, AR | 1 |
| Huang, W | 1 |
| Toutov, AA | 1 |
| Yang, N | 1 |
| Srivastava, K | 1 |
| Geliebter, J | 1 |
| Tiwari, R | 1 |
| Miao, M | 1 |
| Li, XM | 1 |
1 other study available for berberine and Respiratory Syndrome, Acute, Severe
| Article | Year |
|---|---|
A small molecule compound berberine as an orally active therapeutic candidate against COVID-19 and SARS: A computational and mechanistic study.
Topics: Administration, Oral; Antiviral Agents; Berberine; Cell Line; Computer Simulation; COVID-19; COVID-1 | 2021 |